CRB Signs Agreement with Life Technologies
News Jan 20, 2012
The deal extends CRB’s licence to offer dye-labelled primary antibodies as well as peptides.
The agreement means that CRB, which is based in Billingham on Teesside, United Kingdom, is one of the first companies in the world to have such a licence from Life Technologies, the creators of the Molecular Probes dyes, which are used by the Life Science community for imaging purposes.
It extends a deal first signed in 2007 when CRB went into partnership with the Molecular Probes business of the US-based biotechnology tools company.
The Molecular Probes Alexa Fluor® dyes provide a number of benefits including more intense fluorescence than other similar products, better photo-stability allowing more time for image capture, an array of distinct fluorescent colours from blue to infra-red and pH insensitivity that enables the dyes to remain highly fluorescent over a broad pH range.
The initial agreement granted CRB a non-exclusive license to use the full range of Molecular Probes dyes, including Alexa Fluor®, BODIPY®, Oregon Green® and Texas Red® fluorophores, enabling its researchers to benefit from the most comprehensive custom fluorescent labelling service available for peptides.
The extension to the agreement means that CRB, which already has extensive experience of working with modern, smaller dyes for antibody labelling, can now offer labelling of its custom primary antibodies using the Molecular Probes fluorescent dye range.
Emily Humphrys, CRB’s Commercial Director, said: “We are very pleased with this extension to our licence with Life Technologies as it acknowledges our labelling expertise and strengthens our position in the custom dye labelling market.
Humphrys continued, “Our customers will not only benefit from our high quality custom antibody service but also the combination of Life Technologies’ universal dyes.”
Paula Stonemetz, Leader of Cell Systems Out licensing and OEM of Life Technologies, said: “We believe a custom antibody specialist company such as CRB are well-placed to offer custom-dye labelled primary antibodies to their existing customer base in Europe.”
CRB manufactures peptides and antibodies for use in drug discovery and medical research across the world.
Animal venoms are the subject of study at research center based at the Butantan Institute in São Paulo. But in this case, the idea is not to find antidotes, but rather to use the properties of the venoms themselves to identify molecular targets of diseases and, armed with that knowledge, develop new compounds that can be used as medicines.